Use of Captopril in the Diagnosis of Renal Hypertension
- 1 June 1981
- journal article
- research article
- Published by Wiley in Australian and New Zealand Journal of Medicine
- Vol. 11 (3) , 359-363
- https://doi.org/10.1111/j.1445-5994.1981.tb03512.x
Abstract
The effects of a single 25 mg oral dose of captopril on blood pressure, heart rate and circulating renin, angiotensin I, angiotensin II, bradykinin and catecholamine levels were examined in untreated patients with essential (n = 10, group I), accelerated (n = 6, group II) and renal hypertension (n = 8, group III) studied on a normal Na diet. Mean blood pressure fell only slightly in group I patients, (113 .+-. 3 to 109 .+-. 3 mm Hg at 60 min) but a greater fall was observed in group II (153 .+-. 8 to 135 .+-. 11 mm Hg) and a marked fall in group III, (136 .+-. 3 to 114 .+-. 5 mm Hg). There were no significant changes in heart rate in any group. Plasma angiotensin II levels were significantly reduced 30 min after captopril in all 3 groups and returned toward resting values after 4 h. The falls in plasma angiotensin II levels were accompanied by reciprocal increases in blood angiotensin I and plasma renin, but blood brady kinin and plasma catecholamine concentrations remained unchanged. Resting plasma renin levels showed considerable overlap in the 3 groups and the mean renin values were not significantly different in the 3 groups. After captopril, a marked rise in plasma renin concentration (> 2.5 ng/ml per h) was observed in 7 patients in group III, including all 6 patients with renovascular disease. None of the patients with essential hypertension and only 1 patient with accelerated hypertension had such an increase. Determination of the acute renin and blood pressure responses to converting enzyme inhibition with a single oral dose of captopril appears to be useful in identifying patients with renovascular hypertension.Keywords
This publication has 10 references indexed in Scilit:
- Reactive Hyperreninemia in Renovascular Hypertension After Angiotensin Blockade with Saralasin or Converting Enzyme InhibitorAnnals of Internal Medicine, 1979
- Captopril (SQ 14,225) (d-3-mercapto-2-methylpropanoyl-l-proline): A novel orally active inhibitor of angiotensin-converting enzyme and antihypertensive agentProgress in Cardiovascular Diseases, 1978
- Renin, Blood Volume and Response to Saralasin in Patients on Chronic Haemodialysis: Evidence against Volume- and Renin-‘Dependent’ HypertensionClinical Science, 1978
- A sensitive radioenzymatic assay for adrenaline and noradrenaline in plasma.British Journal of Clinical Pharmacology, 1977
- Accentuated Vascular and Endocrine Response to Sq 20881 in HypertensionNew England Journal of Medicine, 1977
- A SPECIFIC ORALLY ACTIVE INHIBITOR OF ANGIOTENSIN-CONVERTING ENZYME IN MANThe Lancet, 1977
- Usefulness and limitations of saralasin, a partial competitive agonist of angiotensin II, for evaluating the renin and sodium factors in hypertensive patientsThe American Journal of Medicine, 1976
- Angiotensin blockade: Its clinical significanceThe American Journal of Medicine, 1976
- ANGIOTENSIN-II BLOCKADE IN MAN BY SAR1-ALA8-ANGIOTENSIN II FOR UNDERSTANDING AND TREATMENT OF HIGH BLOOD-PRESSUREThe Lancet, 1973
- The control of renin releaseThe American Journal of Medicine, 1973